JPMorgan discloses passive 4.0% BMY stake; sole vote 71.7M
Rhea-AI Filing Summary
Bristol-Myers Squibb (BMY): Ownership update. JPMorgan Chase & Co. filed an amended Schedule 13G reporting beneficial ownership of 81,890,781 shares, representing 4.0% of BMY’s common stock as of 09/30/2025.
The filing lists 71,741,508 shares with sole voting power and 790,804 with shared voting power. It also reports 81,264,020 shares with sole dispositive power and 625,305 with shared dispositive power. JPMorgan certified the securities were acquired and are held in the ordinary course of business and not to change or influence control.
Positive
- None.
Negative
- None.
Insights
Passive 13G/A shows JPMorgan at 4.0% of BMY.
JPMorgan reports a 4.0% beneficial stake in BMY (81,890,781 shares) as of 09/30/2025, filed on a Schedule 13G/A, the passive ownership form. The firm details sole vs. shared voting and dispositive powers, indicating typical institutional custody and advisory roles.
The certification states the position is held in the ordinary course and not for influencing control, aligning with 13G eligibility. The stake is below the 5% threshold referenced in the form, a level often associated with fewer heightened reporting triggers.
Actual market impact depends on portfolio and client decisions. Subsequent filings may update ownership levels if they change materially under applicable rules.
FAQ
What did JPMorgan disclose about BMY (Bristol-Myers Squibb) in this 13G/A?
What dispositive power did JPMorgan report over its BMY holdings?
Is JPMorgan’s BMY position passive or for influencing control?
What is the event date referenced in the BMY 13G/A?
Who signed the 13G/A filing and when?
AI-generated analysis. How Rhea-AI works. Not financial advice.